Serum microRNA 125b as a diagnostic or prognostic biomarker for advanced NSCLC patients receiving cisplatin-based chemotherapy

Acta Pharmacologica Sinica

Volumn 34, Issue 2, 2013, Pages 309-313

  Cui, En Hai ^a   Li, Hong Jiao ^b   Hua, Feng ^a   Wang, Bin ^a   Mao, Wei ^a   Feng, Xue Ren ^a   Li, Jian You ^a   Wang, Xiang ^a  

^a HUZHOU CENTRAL HOSPITAL   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

biomarker; cisplatin based chemotherapy; microRNA 125b; non small cell lung cancer (NSCLC); prognosis

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; MESSENGER RNA; MICRORNA 10B; MICRORNA 125B; MICRORNA 155; MICRORNA 34A; NAVELBINE; PACLITAXEL;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; COHORT STUDIES; DIAGNOSIS; FEMALE; HUMANS; LUNG; LUNG NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84873532679     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2012.125     Document Type: Article

References (26)

1. Neville A. Lung cancer. Clin Evid 2005; (14): 1903-20.
2. Bernal Bernal R, Leon Jimenez A, Jaen Olasolo J, Benitez Rodriguez E, Mateo Vallejo F. Local recurrence after non-small cell lung cancer surgery: prognosis variables. An Med Interna 2008; 25: 55-60.
3. Ichinose Y, Tsuchiya R, Yasumitsu T, Koike T, Yamato Y, Nakagawa K, et al. Prognosis of non-small cell lung cancer patients with positive pleural lavage cytology after a thoracotomy: results of the survey conducted by the Japan Clinical Oncology Group. Lung Cancer 2001; 31: 37-41.
4. Okada A, Hirono T, Watanabe T. Safety and prognosis of limited surgery for octogenarians with non-small-cell lung cancer. Gen Thorac Cardiovasc Surg 2012; 60: 97-103.
5. Pathak AK, Bhutani M, Mohan A, Guleria R, Bal S, Kochupillai V. Non small cell lung cancer (NSCLC): current status and future prospects. Indian J Chest Dis Allied Sci 2004; 46: 191-203.
6. Okamoto H, Watanabe K. Medical treatment for stage III non-smallcell lung cancer (NSCLC). Gan To Kagaku Ryoho 2007; 34: 841-8.
7. Brockmoller J, Junker K, Multhoff G. New perspectives in the management of non-small-cell lung carcinoma (NSCLC). Onkologie 2006; 29: 25-8.
8. Chang A. Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC. Lung Cancer 2011; 71: 3-10.
9. Huppi K, Volfovsky N, Mackiewicz M, Runfola T, Jones TL, Martin SE, et al. MicroRNAs and genomic instability. Semin Cancer Biol 2007; 17: 65-73.
10. Leung AK, Sharp PA. Function and localization of microRNAs in mammalian cells. Cold Spring Harb Symp Quant Biol 2006; 71: 29-38.
11. Bagnyukova TV, Pogribny IP, Chekhun VF. MicroRNAs in normal and cancer cells: a new class of gene expression regulators. Exp Oncol 2006; 28: 263-9.
12. Osada H, Takahashi T. MicroRNAs in biological processes and carcinogenesis. Carcinogenesis 2007; 28: 2-12.
13. Pfeffer S, Voinnet O. Viruses, microRNAs and cancer. Oncogene 2006; 25: 6211-9.
14. Cortez MA, Welsh JW, Calin GA. Circulating microRNAs as noninvasive biomarkers in breast cancer. Recent Results Cancer Res 2012; 195: 151-61.
15. Lovat F, Valeri N, Croce CM. MicroRNAs in the pathogenesis of cancer. Semin Oncol 2011; 38: 724-33.
16. Ng EK, Chong WW, Jin H, Lam EK, Shin VY, Yu J, et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 2009; 58: 1375-81.
17. Wei J, Xie L, Taron M, Rosell R, Liu B. Epigenetic alterations of tumor marker microRNAs: towards new cancer therapies. Drug News Perspect 2010; 23: 655-61.
18. Yu DC, Li QG, Ding XW, Ding YT. Circulating microRNAs: potential biomarkers for cancer. Int J Mol Sci 2011; 12: 2055-63.
19. Wang H, Tan G, Dong L, Cheng L, Li K, Wang Z, et al. Circulating miR-125b as a marker predicting chemoresistance in breast cancer. PLoS One 2012; 7: e34210.
20. Ferracin M, Zagatti B, Rizzotto L, Cavazzini F, Veronese A, Ciccone M, et al. MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia. Mol Cancer 2010; 9: 123.
21. Graziano F, Canestrari E, Loupakis F, Ruzzo A, Galluccio N, Santini D, et al. Genetic modulation of the Let-7 microRNA binding to KRAS 3′-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan. Pharmacogenomics J 2010; 10: 458-64.
22. Mathe EA, Nguyen GH, Bowman ED, Zhao Y, Budhu A, Schetter AJ, et al. MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival. Clin Cancer Res 2009; 15: 6192-200.
23. Feng J, Sun X, Sun N, Qin S, Li F, Cheng H, et al. XPA A23G polymorphism is associated with the elevated response to platinum-based chemotherapy in advanced non-small cell lung cancer. Acta Biochim Biophys Sin 2009; 41: 429-35.
24. Yang YQ, Li L, Wang J, Liu XY, Chen XZ, Zhang W, et al. A novel GATA4 loss-of-function mutation associated with congenital ventricular septal defect. Pediatr Cardiol 2012; 33: 539-46.
25. Kong F, Sun C, Wang Z, Han L, Weng D, Lu Y, et al. miR-125b confers resistance of ovarian cancer cells to cisplatin by targeting proapoptotic Bcl-2 antagonist killer 1. J Huazhong Univ Sci Technolog Med Sci 2011; 31: 543-9.
26. Fujita Y, Kojima K, Hamada N, Ohhashi R, Akao Y, Nozawa Y, et al. Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells. Biochem Biophys Res Commun 2008; 377: 114-9.